Two Sigma Advisers LP cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 493,258 shares of the company’s stock after selling 78,400 shares during the period. Two Sigma Advisers LP’s holdings in IDEXX Laboratories were worth $77,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of IDXX. Zions Bancorporation bought a new position in IDEXX Laboratories during the third quarter worth about $162,000. Benjamin F. Edwards & Company Inc. increased its position in IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after acquiring an additional 1,000 shares during the period. SignalPoint Asset Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $200,000. Ledyard National Bank increased its position in IDEXX Laboratories by 58.9% during the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after acquiring an additional 480 shares during the period. Finally, Unio Capital LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $203,000. 87.09% of the stock is currently owned by institutional investors.
IDXX has been the topic of a number of recent research reports. Piper Jaffray Companies initiated coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America raised their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Finally, Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $194.00.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.04. The firm had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.58 earnings per share. equities analysts predict that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.
In other IDEXX Laboratories news, Director Daniel M. Junius sold 2,974 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $190.06, for a total transaction of $565,238.44. Following the sale, the director now directly owns 5,602 shares in the company, valued at $1,064,716.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce L. Claflin acquired 1,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were purchased at an average price of $179.58 per share, for a total transaction of $179,580.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $179,580. The disclosure for this purchase can be found here. Insiders have sold 91,736 shares of company stock worth $16,193,502 over the last quarter. Corporate insiders own 2.77% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://sportsperspectives.com/2018/03/14/idexx-laboratories-inc-idxx-shares-sold-by-two-sigma-advisers-lp.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.